Recursion Pharma Appoints New CMO, CBO; Gibson Departs
Ticker: RXRX · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $5,000,000, $2,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, personnel
Related Tickers: RXRX
TL;DR
New CMO & CBO in, old CMO out at Recursion Pharma. Big leadership shakeup.
AI Summary
Recursion Pharmaceuticals, Inc. announced on December 2, 2024, the appointment of Dr. Amy Abernethy as Chief Medical Officer and Dr. Laura LaVoie as Chief Business Officer. The company also reported the departure of Dr. Christopher Gibson from his role as Chief Medical Officer, effective December 2, 2024. These changes are part of the company's ongoing strategic initiatives.
Why It Matters
These executive changes could signal shifts in the company's strategic direction for drug development and business partnerships.
Risk Assessment
Risk Level: medium — Executive changes can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- Recursion Pharmaceuticals, Inc. (company) — Registrant
- Dr. Amy Abernethy (person) — Appointed Chief Medical Officer
- Dr. Laura LaVoie (person) — Appointed Chief Business Officer
- Dr. Christopher Gibson (person) — Departed Chief Medical Officer
- December 2, 2024 (date) — Effective date of changes
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Amy Abernethy has been appointed as the new Chief Medical Officer.
Who has been appointed as the new Chief Business Officer?
Dr. Laura LaVoie has been appointed as the new Chief Business Officer.
Who has departed from their role as Chief Medical Officer?
Dr. Christopher Gibson has departed from his role as Chief Medical Officer.
When were these executive changes effective?
These changes were effective as of December 2, 2024.
What is the company's ticker symbol?
The company's ticker symbol is RXRX.
Filing Stats: 844 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2024-12-03 16:40:55
Key Financial Figures
- $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar
- $5,000,000 — , which will have an aggregate value of $5,000,000, consisting of restricted stock units w
- $2,500,000 — restricted stock units with a value of $2,500,000 and stock options with a value of $2,50
Filing Documents
- rxrx-20241202.htm (8-K) — 22KB
- 0001601830-24-000232.txt ( ) — 154KB
- rxrx-20241202.xsd (EX-101.SCH) — 2KB
- rxrx-20241202_def.xml (EX-101.DEF) — 3KB
- rxrx-20241202_lab.xml (EX-101.LAB) — 23KB
- rxrx-20241202_pre.xml (EX-101.PRE) — 14KB
- rxrx-20241202_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 3, 2024. RECURSION PHARMACEUTICALS, INC. By: /s/ Christopher Gibson Christopher Gibson Chief Executive Officer